Clinical observation of primary extranasal nasal-type NK/T cell lymphoma treated with P-GEMOX as a first-line regimen
10.3760/cma.j.cn115356-20191006-00193
- VernacularTitle:P-GEMOX方案一线治疗原发鼻外鼻型NK/T细胞淋巴瘤临床观察
- Author:
Lina HU
1
;
Mian XIE
;
Guoqiang LI
;
Chun FENG
;
Peng KE
;
Xinyou ZHANG
;
Jihao ZHOU
Author Information
1. 暨南大学第二临床医学院 深圳市人民医院血液内科 518000
- From:
Journal of Leukemia & Lymphoma
2020;29(3):160-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of P-GEMOX (pegaspargase, gemcitabine and oxaliplatin) as a first-line regimen for the treatment of primary extranasal nasal-type NK/T cell lymphoma (NKTCL).Methods:The clinical manifestations, treatment response and prognosis of 7 patients with primary extranasal nasal-type NKTCL who underwent P-GEMOX chemotherapy as a first-line therapy in Shenzhen People's Hospital from September 2015 to October 2018 were retrospectively analyzed.Results:The median age of 7 patients with primary extranasal nasal-type NKTCL was 41 years old (27-74 years old), which was more commonly found in males (6 cases); the primary and invading extranasal sites included ileocecal, lymph nodes, skin, testis, adrenal gland, central nervous system, etc. The P-GEMOX regimen was used as a first-line therapy, although some patients had a short-term effect, all patients eventually progressed rapidly and died. The overall survival time was 2 weeks to 21 months.Conclusion:The short-term efficacy of P-GEMOX as a first-line therapy for the treatment of primary extranasal nasal-type NKTCL is acceptable, but the long-term efficacy is poor.
